Pemazyre Wins Cost-Effectiveness Thumbs Up For Rare Bile Duct Cancer In England
NICE Said No To Bavencio For Urothelial Cancer
Executive Summary
Bavencio, Taltz, Cosentyx, and Opdivo plus Yervoy were this week also the subject of final recommendations from the health technology assessment body, NICE, on whether or not they should be used on the National Health Service for certain indications.
You may also be interested in...
NICE Overturns Bavencio Rejection After Merck/Pfizer Win Appeal On English Funding
As well as now backing the reimbursement of Bavencio for urothelial cancer, the health technology assessment institute has recommended Koselugo, for neurofibromatosis type 1, and Evenity, the osteoporosis drug that will now target over 20,000 people in England and Wales. On the other hand, Piqray has for now been turned down for advanced breast cancer.
No To Five, Yes To Three: NICE Decides On Funding For Drugs In England
Pfizer has been unsuccessful in its appeal against the health technology assessment body’s rejection of the rare heart disease drug, Vyndaqel. Meanwhile, Dr Falk Pharma has received the all-clear to make Jorveza (budesonide) available on the National Health Service for eosinophilic esophagitis.
Upstaza: First Gene Therapy For Ultra-Rare Disorder AADC Deficiency Receives English Funding
The single-dose gene therapy for aromatic L-amino acid decarboxylase in children is to be made available on the National Health Service following a confidential commercial deal between NHS England and PTC Therapeutics.